8-K: Lyra Therapeutics Reports Positive Phase 3 Results for LYR-210 in Chronic Rhinosinusitis, Implements 1-for-50 Reverse Stock Split

Lyra Therapeutics announced positive results from its ENLIGHTEN 2 Phase 3 trial for LYR-210 in chronic rhinosinusitis, meeting primary and key secondary endpoints, alongside the implementation of a 1-for-50 reverse stock split.

Summary

• Lyra Therapeutics, Inc. (LYRA) filed an 8-K reporting a 1-for-50 reverse stock split of its common stock, effective May 27, 2025, at 5:00 p.m. Eastern Time, with split-adjusted trading commencing May 28, 2025.
• The reverse stock split was approved by stockholders on May 14, 2025, and the Board of Directors approved the 1-for-50 ratio on the same date.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment in lieu thereof.
• The number of authorized shares of Common Stock and the par value of $0.001 per share remain unchanged.
• The company announced positive results from the ENLIGHTEN 2 Phase 3 clinical trial of LYR-210 for chronic rhinosinusitis (CRS), meeting its primary endpoint.
• LYR-210 demonstrated a statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (-1.13; p=0.0078) in patients without nasal polyps.
• Key secondary endpoints were also met, including statistically significant improvement in 3CS in the full population (-0.90; p=0.0209) and SNOT-22 score at 24 weeks (-8.7; p=0.0101).
• Symptom improvement was observed as early as week 4 for SNOT-22, with a clinically meaningful improvement of -22.4 points from baseline in the LYR-210 group.
• LYR-210 was well-tolerated with a safety profile similar to sham control, and no product-related serious adverse events were reported.
• Pooled data from ENLIGHTEN 1 and ENLIGHTEN 2 trials in 64 CRS patients with small nasal polyps (grade 1) showed a consistent positive trend over 24 weeks in multiple efficacy endpoints, though not statistically significant.
• The company plans to review the totality of the ENLIGHTEN dataset to optimize its regulatory strategy and align with the FDA for an NDA submission in non-polyp patients.
• A Phase 3 trial for CRS patients with nasal polyps is planned to initiate in 1H 2026, subject to additional financing, with co-primary endpoints of Nasal Congestion Score (NCS) and Nasal Polyp Score (NPS) at Week 24.
• The ENLIGHTEN 1 trial, previously reported in May 2024, did not meet its primary or secondary endpoints.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful outcome of the ENLIGHTEN 2 Phase 3 trial, which met its primary and key secondary endpoints, offering a clear path forward for LYR-210 in non-polyp CRS patients. This is a significant clinical achievement. However, the sentiment is tempered by the previous failure of the ENLIGHTEN 1 trial, the non-statistically significant results in the pooled polyp analysis, and the explicit mention of the need for substantial additional financing for future development, which introduces funding risk.

Positives

• The ENLIGHTEN 2 Phase 3 trial met its primary endpoint, demonstrating statistically significant improvement in the composite of three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) in patients without nasal polyps.
• Key secondary endpoints were also met, showing statistically significant improvement in 3CS in the full population (p=0.0209) and SNOT-22 score at 24 weeks (p=0.0101).
• Symptom improvement with LYR-210 was observed as early as week 4 for SNOT-22 and sustained throughout the trial, with a clinically meaningful improvement of -22.4 points from baseline.
• LYR-210 demonstrated a favorable safety profile, being well-tolerated with no product-related serious adverse events reported.
• Pooled data from ENLIGHTEN 1 and ENLIGHTEN 2 trials showed a consistent positive trend in multiple efficacy endpoints for CRS patients with small nasal polyps, supporting future development in this population.
• The company has received FDA feedback in December 2024 on study design for CRS with nasal polyps, indicating alignment on endpoints, inclusion criteria, patient population, background therapy, and assessments for a future trial.
• The reverse stock split is intended to increase the per-share trading price, potentially helping the company maintain its listing on The Nasdaq Capital Market.

Negatives

• The ENLIGHTEN 1 Phase 3 trial, part of the same program, previously failed to meet its primary and secondary endpoints in May 2024.
• The pooled analysis for CRS patients with nasal polyps showed a 'consistent positive trend' but did not achieve statistical significance for any of the measured endpoints (e.g., 3CS p=0.0837, SNOT-22 p=0.1331, ethmoid opacification p=0.1127).
• Numerical improvement in ethmoid sinus opacification in ENLIGHTEN 2 was not statistically significant (p=0.1809).
• The company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future.
• The planned Phase 3 trial for CRS with nasal polyps is 'subject to additional financing,' indicating a potential funding gap.
• The failure of the ENLIGHTEN 1 trial has made it more difficult for the company to raise capital and led to the termination of approximately 87 employees in May 2024, significantly affecting operations.

Risks

• The company's failure to meet its primary endpoint in the ENLIGHTEN 1 Phase 3 clinical trial.
• The company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future.
• The company's need for substantial additional funding, which may not be available, including for another Phase 3 trial for LYR-210.
• The company's ability to continue as a going concern is uncertain.
• The company has a limited operating history and no approved products.
• Clinical trial data is subject to change until the completion of the applicable clinical study report.
• Clinical trials required for the company's product candidates are expensive, time-consuming, and their outcome is uncertain.
• Potential inability to obtain required regulatory approvals for LYR-210.
• Effects of recently enacted and future legislation, system failures, security breaches, and significant competition.
• Reliance on third parties to conduct preclinical studies and clinical trials.
• Failure to obtain and maintain or adequately protect the company's intellectual property rights.
• Failure to retain key personnel or to recruit qualified personnel.
• The price of the company's common stock may be volatile and fluctuate substantially.
• Significant costs and required management time as a result of operating as a public company and potential securities class action litigation.
• Challenges and delays in scaling in-house manufacturing capabilities for clinical trials and commercial supply.
• Inability to establish and maintain collaborative relationships.
• Reliance on certain suppliers critical to production.
• Difficulties in managing the company's growth.
• Effects of natural disasters, terrorism, wars, and global pandemics.

Future Outlook

Lyra Therapeutics plans to review the totality of the ENLIGHTEN trial data to optimize its regulatory strategy for LYR-210. The company intends to align with the FDA on a path forward for an NDA submission in patients without nasal polyps. Based on positive pooled data and prior FDA alignment, Lyra also plans to proceed with a development plan for LYR-210 in patients with nasal polyps, with a Phase 3 trial targeted to initiate in the first half of 2026, contingent on securing additional financing. The company envisions LYR-210 benefiting both non-polyp and polyp patients, positioning it as a leader in CRS and validating its platform for future ENT indications.

Management Comments

• "We are thrilled to announce these positive results from our ENLIGHTEN 2 trial. We believe this has the potential to provide a path to advance LYR-210 to treat CRS, offering six months of therapy in a single administration for millions of patients who do not respond to standard CRS medical management. We will continue to review the totality of the dataset from the ENLIGHTEN trials to optimize our regulatory strategy." Maria Palasis, Ph.D., President and CEO, Lyra Therapeutics.
• "Given these data we reported today, we plan to align with the FDA on a path forward for an NDA submission in patients without nasal polyps. As planned, we also analyzed the pooled data from ENLIGHTEN 2 and ENLIGHTEN 1 trials to treat CRS patients with nasal polyps, and we believe this positive data positions us to proceed with a development plan in patients with nasal polyps, based on our alignment in December 2024 with FDA on endpoints, inclusion criteria, patient population, background therapy, and assessments." Maria Palasis, Ph.D., President and CEO, Lyra Therapeutics.
• "Looking further ahead, we envision LYR-210 achieving its potential to benefit both non-polyp and polyp patients, positioning us to become a leader in CRS and validating our platform for future ENT indications." Maria Palasis, Ph.D., President and CEO, Lyra Therapeutics.
• "The positive results seen in the ENLIGHTEN 2 study are impressive and represent what could be a promising new treatment approach for the many CRS patients that I see every day in my practice who are underserved by limited therapies. The more than 20-point improvement from baseline in SNOT-22 score after LYR-210 treatment represents a clinically meaningful improvement in patient symptoms." Zachary Soler, M.D., MSc, Professor in the Department of Otolaryngology-Head and Neck Surgery at the Medical University of South Carolina and coordinating Lead Investigator for the ENLIGHTEN 2 trial.
• "These positive results represent a significant milestone in advancing an innovative treatment to CRS patients who suffer from this chronic condition. Its a proud moment for us and a testament to the dedication of this team and our investigators in the development of this novel therapy." Harlan Waksal, M.D., Executive Chairman, Lyra Therapeutics.

Industry Context

Chronic Rhinosinusitis (CRS) is a highly prevalent inflammatory disease affecting approximately 12% of the U.S. population, with about 4 million patients annually failing medical management. The market is significantly underserved, with nearly 80% of patients not benefiting from current treatments. Existing therapies like topical steroid sprays (e.g., Xhance) have comparable performance to inexpensive over-the-counter options, and surgery often leads to recurrence. Biologics (e.g., Dupixent) are reserved for severe polyp cases (Grade 3-4) and Type 2 inflammation, leaving a large unmet need. Lyra's LYR-210, a long-acting, bioabsorbable sinonasal implant, aims to provide six months of continuous anti-inflammatory therapy with a single office-based procedure, positioning it as a potential new standard of care for both non-polyp and polyp CRS patients, addressing a multi-billion dollar market opportunity.

Comparison to Industry Standards

• LYR-210 is designed to be the only product candidate providing 6 months of CRS therapy with a single treatment, differentiating it from daily or frequent administration methods.
• Unlike Xhance, which has clinical performance comparable to inexpensive, over-the-counter topical steroid sprays, LYR-210 aims to provide sustained, localized drug delivery for improved efficacy.
• Current surgical interventions for CRS do not treat the underlying cause, with 65% of surgical patients experiencing recurring CRS and 20% requiring revision surgery; LYR-210 aims to offer a non-surgical, long-acting alternative or adjunct.
• Biologics like Dupixent, while effective, are reserved for the most severe cases (Grade 3-4 nasal polyps, representing only 27.5% of patients) due to systemic exposure and high cost, whereas LYR-210 targets a broader patient population, including those without polyps or with smaller polyps.
• Lyra's approach aims to address the ~4 million CRS patients in the United States who fail medical management each year, a significant portion of whom are not served by existing advanced treatments.

Corporate Governance

Stakeholder Impact

• **Shareholders**: The 1-for-50 reverse stock split will reduce the number of shares held by each shareholder, increasing the per-share price. This may help maintain Nasdaq listing compliance but does not change the total value of their holdings immediately. Future capital raises, if dilutive, could impact shareholder value.
• **Patients**: Positive ENLIGHTEN 2 results offer hope for a new, long-acting treatment option (LYR-210) for chronic rhinosinusitis, particularly for those without nasal polyps, potentially improving quality of life.
• **Employees**: The previous reduction in force following ENLIGHTEN 1 failure indicates past negative impact. Future success and funding for new trials could stabilize or grow the workforce.
• **Investment Professionals/Analysts**: The positive ENLIGHTEN 2 data provides a clearer clinical path for LYR-210, enabling more informed valuation and investment decisions, though funding needs remain a key consideration.
• **Regulatory Authorities (FDA)**: The company's plans for NDA submission and further development in polyp patients will involve continued interaction and review by the FDA.

Next Steps

• Review the totality of the dataset from the ENLIGHTEN trials to optimize regulatory strategy.
• Align with the FDA on a path forward for an NDA submission for LYR-210 in patients without nasal polyps.
• Proceed with a development plan for LYR-210 in patients with nasal polyps, based on prior FDA alignment.
• Initiate a Phase 3 clinical trial for CRS with nasal polyps in 1H 2026, subject to additional financing.
• Present results from the ENLIGHTEN 2 trial at the 71st Annual Meeting of the American Rhinologic Society in October 2025.
• Complete CMC (Chemistry, Manufacturing, and Controls) package at the Waltham manufacturing facility.

Key Dates

Recommendation

Keywords

Chronic Rhinosinusitis, CRS, LYR-210, Phase 3 Clinical Trial, ENLIGHTEN 2, Nasal Polyps, Sinonasal Implants, Mometasone Furoate, Biotechnology, Drug Development, Reverse Stock Split, Nasdaq, SEC Filing, Biopharmaceutical, Otolaryngology